Literature DB >> 2661250

Beta-haemolytic streptococci from the female genital tract: clinical correlates and outcome of treatment.

R F Lewis1.   

Abstract

Clinical features, treatment and outcome were assessed retrospectively by means of a questionnaire in 174 patients in general practice whose vaginal swabs yielded beta-haemolytic streptococci. These were compared with 96 patients whose swabs yielded no recognized microbial pathogens. Patients with group B streptococci did not differ in any of these parameters from the control group, but those with group A streptococci were more likely to have vaginal soreness, a purulent discharge, and to respond to anti-streptococcal antibiotics. Implications for laboratory reporting are discussed.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2661250      PMCID: PMC2249466          DOI: 10.1017/s0950268800030107

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   2.451


  10 in total

1.  Haemophilus vaginalis vaginitis: a newly defined specific infection previously classified non-specific vaginitis.

Authors:  H L GARDNER; C D DUKES
Journal:  Am J Obstet Gynecol       Date:  1955-05       Impact factor: 8.661

2.  Quantitative bacteriology of the vaginal flora during the menstrual cycle.

Authors:  M Wilks; S Tabaqchali
Journal:  J Med Microbiol       Date:  1987-11       Impact factor: 2.472

3.  Normal vaginal microbiology of women of childbearing age in relation to the use of oral contraceptives and vaginal tampons.

Authors:  C A Morris; D F Morris
Journal:  J Clin Pathol       Date:  1967-07       Impact factor: 3.411

4.  Prevalence of Gardnerella vaginalis.

Authors:  K G Kerr; M R Millar; P Hawkey; P G Godwin
Journal:  Br Med J (Clin Res Ed)       Date:  1988-05-28

Review 5.  Group G streptococcal infections.

Authors:  P N Gaunt; D V Seal
Journal:  J Infect       Date:  1987-07       Impact factor: 6.072

6.  Microbial flora of the lower genital tract during pregnancy: relationship to morbidity.

Authors:  J de Louvois; R Hurley; V C Stanley
Journal:  J Clin Pathol       Date:  1975-09       Impact factor: 3.411

7.  Group B streptococci in the female genital tract.

Authors:  R G Finch; G L French; I Phillips
Journal:  Br Med J       Date:  1976-05-22

8.  Morbidity of the lower genital tract during pregnancy.

Authors:  V C Stanley; J B Jones; R Hurley; J E Foulkes; J de Louvois
Journal:  J Clin Pathol       Date:  1975-09       Impact factor: 3.411

9.  Aerobic and anaerobic flora of the cervix during pregnancy and the puerperium.

Authors:  C P Goplerud; M J Ohm; R P Galask
Journal:  Am J Obstet Gynecol       Date:  1976-12-01       Impact factor: 8.661

10.  Anaerobic vaginosis (non-specific vaginitis): clinical, microbiological, and therapeutic findings.

Authors:  A L Blackwell; A R Fox; I Phillips; D Barlow
Journal:  Lancet       Date:  1983-12-17       Impact factor: 79.321

  10 in total
  4 in total

1.  Streptococcus pyogenes vulvovaginitis in children in Nottingham.

Authors:  F E Donald; R C Slack; G Colman
Journal:  Epidemiol Infect       Date:  1991-06       Impact factor: 2.451

2.  Association between group A beta-haemolytic streptococci and vulvovaginitis in adult women: a case-control study.

Authors:  M J Bruins; R A M J Damoiseaux; G J H M Ruijs
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-04-03       Impact factor: 3.267

3.  Genome-Wide Screens Identify Group A Streptococcus Surface Proteins Promoting Female Genital Tract Colonization and Virulence.

Authors:  Luchang Zhu; Randall J Olsen; Stephen B Beres; Matthew Ojeda Saavedra; Samantha L Kubiak; Concepcion C Cantu; Leslie Jenkins; Prasanti Yerramilli; Layne Pruitt; Amelia R L Charbonneau; Andrew S Waller; James M Musser
Journal:  Am J Pathol       Date:  2020-03-19       Impact factor: 4.307

4.  Group B streptococcus carriage and vulvovaginal symptoms: causal or casual? A case-control study in a GUM clinic population.

Authors:  C Shaw; M Mason; A Scoular
Journal:  Sex Transm Infect       Date:  2003-06       Impact factor: 3.519

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.